Biotech: Page 59
-
PharmaVoice Team/PharmaVoice
Table of Contents
on the cover The time for transparency The government, medical journal editors, and general public are clamoring for the pharmaceutical industry to provide complete information about ongoing and completed clinical trials. There has been a flurry of activity, announcements, and mandates in this ar...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
June 6-7 Pharmaceutical Marketers KnowledgeShare Forum 2005: Building Brand Differentiation in the Current Regulatory Climate Airport Marriott, Philadelphia This is a PharmaVOICE event, subscribers are eligible for a 15% discount; register using code PVMKS05. For more information, contact Micah L...
By PharmaVoice Team • Jan. 2, 2008 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
David King -- Regal Legal
Regal Legal By Kim Ribbink June 2005 PharmaVOICE From biotech’s early days in the mid-1980s, David R. King has played a central role in the industry, gaining a deep appreciation for science, the broad range of phases of business development, and what it takes to succeed. Years of experience repre...
By Kim Ribbink • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
November 18-20, 2003, Westin Copley Place — Boston LogiPharma 2003 This is an opportunity for attendees to hear how competitors and peers are maximizing every facet of their supply-chain strategy. The event provides the opportunity to hear more than 25 confirmed case studies delivered by senior-l...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharma POOL Michael J. DuBois Jeffrey A. Winton Schering-Plough Announces VP Appointments Schering-Plough, Kenilworth, N.J., has appointed Michael J. DuBois senior VP of global licensing. In this role, Mr. DuBois, 56, is responsible for the acquisition of new products discovered outside Schering-...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Letter from the Editor A world of opportunity Having attended the past four annual Biotechnology Industry Organization (BIO) conferences, I look forward to once again walking the show floor and attending this year’s sessions to learn about the many new innovations that promise to define the glo...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
It's All About Changing Practice
It’s All About Changing Practice Each and every step along the drug-development path must focus on the end game — to define the place of a new drug in practice, and then to communicate the data clearly and consistently using all available channels. But can companies make themselves heard in th...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Creating a Guidance System for Life-Science Brands
Creating a Guidance System for Life-Science Brands While meaningful biomedical research depends on proteomics, genetics, and genomics tools, their ultimate application also will depend on successful commercialization and marketing tools. Mark Stinson President ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Personalized Medicine: Our Industry's Next Great Leap Forward
Personalized Medicine: Our Industry’s Next Great Leap Forward Marketing Personalized medicine will drive medicine to become much more of a science than an art. And with that change, there will be many necessary fundamental changes to how our industry markets these innovations. Ri...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Recruitment: To Centralize or Decentralize? This is the Question.
Recruitment: To Centralize or Decentralize? This is the Question. Liz Moench President and CEO Patient and Investigator Recruitment In many people’s minds, centralized recruitment often symbolizes big money and big studies. But in actuality, nothing could...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Strategic Phase II Planning -- More Important Than Ever for the Biotech Industry
Strategic Phase II Planning — More Important Than Ever for the Biotech Industry Lukas Makris, Ph.D. CEO Phase II programs should not only be judged on how well the objectives were met, but on how well they might predict the Phase III outcome. The biotechnology industr...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Marketing Strategies for Emerging Companies: Lessons from the Maine Wilderness
Marketing Strategies for Emerging Companies: Lessons from the Maine Wilderness for Biotech and Biopharma I do not consider a sale complete until the goods are worn out and the customer (sic) is still satisfied.” When Leon Leonwood Bean posted those words in his humble Maine store in 1916 he wa...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Branding Your Company -- Right from the Start
Branding Your Company — Right from the Start Executives of emerging biotech companies face myriad challenges. While they may certainly understand the value of branding and marketing, those functions may command less of their attention during the early stages of company development than the challe...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
A Robust Future for Phase IV Trials
A Robust Future for Phase IV Trials May 2005 VIEW on Biotechnology Clinical Trials Dimensional HealthCare Inc., Cedar Knolls, N.J., designs, implements, and provides community-based research to the pharmaceutical and medical-device industries, focusing on the design and implementation of la...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Table of Contents
Table of contents Letter from the Editor The Forum Biotech: The Perfect Storm — A relatively more favorable funding environment, cutting-edge technologies, and a strong position at the partnership table have many of today’s biotechnology companies in a position for success. Company Listing by Top...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
The Next BIG Thing in EDC
The Next BIG Thing in EDC The most compelling evidence for the argument that electronic data capture (EDC) is entering the mass adoption phase of its technology life cycle is the rate at which sponsors and CROs are internalizing the development processes. Technology transfer or in-licensing o...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Giving Birth to a Healthy Brand
Joseph Doyle, R.Ph. Chief Branding and Strategy Officer Giving Birth to a Healthy Brand the promotional mix Closely aligning clinical and marketing strategies early in development is the way to ensure that a brand will be born healthy. It seems that no matter what the br...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
May 16-17 Global Clinical Trials Hyatt Regency Jersey City, Jersey City, N.J. For more information, contact Caria Badenhorst, Marcus Evans, at 246-417-5321, e-mail [email protected], or visit marcusevans.com. May 16-17 5th Annual Sample Accountability Hyatt Regency Princeton, Princeton, N....
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Table of Contents
On the Cover Culture of compliance: Cutting through the confusion To be compliant with the many regulations and guidances that apply to the marketing of prescription products, companies need to create a culture of compliance that fosters and promotes an ethical atmosphere and compliant behavior. ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
The Art of the Deal
The biotech industry is in a much stronger position now than it was in its early days, and today biotech companies enjoy a prominent seat at the negotiation table. Biotech companies, especially those with products, are asking for true collaboration instead of relying on licensing deals. The days ...
By Denise Myshko • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
What's on Your Mind -- Opinions
Opinions More on Leadership Development PharmaVOICE received such an overwhelming response to our leadership development opinion question — how executives throughout the industry develop leaders — for the April issue, we are pleased to publish additional insights on this hot topic. Entrepreneuria...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
February 15-17 WCBF Six Sigma in Chemicals & Pharmaceuticals Hyatt Regency Dallas, Dallas For more information, contact Louise Gosling, WCBF Six Sigma Solutions, at 44-14-83 76-0883, e-mail [email protected], or visit wcbf.com. February 15-18 18th Annual DIA Electronic Document Manageme...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Cover
PharmaVOICE The Forum for the Industry Executive Year In Preview: 2005 More than 100 experts talk about the industry’s future www.pharmavoice.com December 2004 Special Issue Volume 4 Number 12 Download PDF
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Table of Contents
Contents Kristine Nash-Wong, Marketing Manager at HealthMedia, speaks about reputation enhancement. Dr. Thomas Wicks, VP of Regulatory Affairs at Odyssey Pharmaceuticals, talks about continuing treatment innovation while limiting costs. Scott Szwast, Sector Marketing Manager at UPS Supply Chain S...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
2005 Year In Preview Taren Grom In keeping with PharmaVOICE’s mission of providing insightful and provocative commentary on the business practices, strategies, and services that affect the life cycle of products from molecule through market, it is our pleasure to publish the first annual Year in ...
By Taren Grom • Jan. 2, 2008
Previous
